Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease

Hong Xu, Ali Hashem, Anna Witasp, Rik Mencke, David Goldsmith, Peter Barany, Annette Bruchfeld, Annika Wernerson, Juan-Jesus Carrero, Hannes Olauson*

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    12 Citations (Scopus)
    3 Downloads (Pure)


    Background. Recent studies suggest that the phosphaturic hormone fibroblast growth factor 23 (FGF23) is involved in regulation of renal sodium excretion and blood pressure. There is evidence of both direct effects via regulation of the sodiumchloride symporter (NCC) in the distal tubule, and indirect effects through interactions with the renin-angiotensinaldosterone system. However, clinical data on the association between FGF23 and renal sodium regulation is lacking. Herein, we investigated the associations of FGF23 with renal sodium handling and blood pressure in non-dialysis CKD patients.

    Methods. This was a cross-sectional study encompassing 180 CKD patients Stage 1-5, undergoing renal biopsy. Plasma intact FGF23, 24-h urinary sodium excretion, fractional excretion of sodium (FENa) and blood pressure were measured at baseline. The association between FGF23 and renal sodium handling was explored by multivariate regression analysis.

    Results. The median age was 52.8 years, 60.6% were men and the median estimated glomerular filtration rate (eGFR) was 50.6mL/min/1.73m(2). In univariate analysis, FGF23 was positively associated with FENa (Spearman's rho = 0.47; P<0.001) and systolic blood pressure (rho = 0.17, P<0.05), but not with plasma sodium, 24-h urinary sodium excretion or mean arterial blood pressure. The association between FGF23 and FENa remained significant after adjustment for potential confounders (multivariable adjusted beta coefficient 0.60, P<0.001). This association was stronger among the 107 individuals with eGFR

    Conclusions. FGF23 is independently associated with increased FENa in non-dialysis CKD patients. These data do not support the notion that FGF23 causes clinically significant sodium retention. Further studies are warranted to explore the mechanism underlying this association.

    Original languageEnglish
    Pages (from-to)2051-2057
    Number of pages7
    JournalNephrology Dialysis Transplantation
    Issue number12
    Publication statusPublished - Dec-2019


    • cardiovascular disease
    • FGF23
    • hypertension
    • renal sodium handling
    • KLOTHO

    Cite this